Ascentage Pharma: Wang Shaomeng Files Initial Ownership Statement
| Field | Detail |
|---|---|
| Company | Wang Shaomeng |
| Form Type | 3 |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, form-3, initial-statement, transparency
TL;DR
**New insider Wang Shaomeng just filed a Form 3 for Ascentage Pharma, signaling initial beneficial ownership.**
AI Summary
Wang Shaomeng, a new insider at Ascentage Pharma Group International (CIK: 0002023311), filed a Form 3 on March 23, 2026, indicating their initial beneficial ownership of securities as of March 18, 2026. This filing is crucial for investors because it signals that Shaomeng has taken on a role that grants them access to non-public information, and their future trading activity could provide insights into the company's prospects.
Why It Matters
This filing matters because it introduces a new insider, Wang Shaomeng, to Ascentage Pharma, whose future stock transactions could signal confidence or concern about the company's direction.
Risk Assessment
Risk Level: low — A Form 3 filing itself is a routine disclosure and does not inherently carry significant risk, but rather provides transparency.
Analyst Insight
Smart investors should add Wang Shaomeng to their insider tracking list for Ascentage Pharma Group International and monitor future Form 4 filings for any buying or selling activity, which could provide signals about the company's future.
Key Players & Entities
- Wang Shaomeng (person) — Reporting Person
- Ascentage Pharma Group International (company) — Issuer
- 0002122971 (person) — CIK of Wang Shaomeng
- 0002023311 (company) — CIK of Ascentage Pharma Group International
FAQ
What is the purpose of Wang Shaomeng's Form 3 filing?
The Form 3 filing by Wang Shaomeng on March 23, 2026, serves as an 'Initial statement of beneficial ownership of securities,' indicating their first disclosure of ownership in Ascentage Pharma Group International as of the report period end date, March 18, 2026.
When was the Form 3 filed and accepted by the SEC?
The Form 3 was filed on March 23, 2026, and accepted by the SEC on the same day at 19:13:53.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 8 · Accepted 2026-03-23 19:13:53
Filing Documents
- marketforms-72705.html (3)
- marketforms-72705.xml (3) — 7KB
- poa.htm (EX-24) — 6KB
- 0001213900-26-033127.txt ( ) — 14KB
From the Filing
SEC FORM 3 SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Wang Shaomeng (Last) (First) (Middle) 700 KING FARM BLVD, STE 510 (Street) ROCKVILLE MARYLAND 20850 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares 1,193,032 D Ordinary Shares 2,836,845 I See Footnote (1) (1) Ordinary Shares 6,024,066 I See Footnote (2) (2) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Options (3) 11/26/2035 Ordinary Shares 17,965 $ 8.14 (4) D Restricted share units (5) (5) Ordinary Shares 27,965 $ 0 D Explanation of Responses: 1. Held by KEW Trust. 2. Held by Shaomeng Wang Dynasty Trust. 3. The stock options vest in twelve (12) tranches equally on the 26th of the month starting November 26, 2025. 4. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. 5. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. Remarks: This form is filed using a special power of attorney. Thomas J. Knapp 03/20/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26)